Cargando…
Tirbanibulin Attenuates Pulmonary Fibrosis by Modulating Src/STAT3 Signaling
Tirbanibulin (KX-01) is the first clinical Src inhibitor of the novel peptidomimetic class that targets the peptide substrate site of Src providing more specificity toward the Src kinase. This study assessed the impact of KX-01 on cobalt chloride (CoCl(2))-treated L929 cells and bleomycin (BLM)-indu...
Autores principales: | Wang, Xin, Ren, Rui, Xu, Zehui, Huang, Haidi, Jiang, Wanglin, Ma, Jinbo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326405/ https://www.ncbi.nlm.nih.gov/pubmed/34349652 http://dx.doi.org/10.3389/fphar.2021.693906 |
Ejemplares similares
-
Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo
por: Zhang, Xue, et al.
Publicado: (2019) -
Wedelolactone Attenuates Pulmonary Fibrosis Partly Through Activating AMPK and Regulating Raf-MAPKs Signaling Pathway
por: Yang, Jin-yu, et al.
Publicado: (2019) -
1% Tirbanibulin Ointment for the Treatment of Actinic
Keratoses
por: Dao, Diem-Phuong D., et al.
Publicado: (2021) -
Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action
por: Schlesinger, Todd, et al.
Publicado: (2022) -
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results
por: Hong, Jin-Bon, et al.
Publicado: (2022)